Tumors of low malignant potential (LMP) represent 20% of epithelial ovarian cancers (EOCs) and are associated with a better prognosis than the invasive tumors (TOV). Defining the relationship between LMPs and TOVs remains an important goal towards understanding the molecular pathways that contribute to prognosis, as well as providing molecular markers, for these EOCs. To this end, DNA microarray analyses were performed either in a primary culture or a tumor tissue model system and selected candidate genes showing a distinctive expression profile between LMPs and TOVs were identified using a class prediction approach based on three statistical methods of analysis. Both model systems appear relevant as candidate genes identified by either model allowed the proper reclassification of samples as either LMPs or TOVs. Selected candidate genes (CAS, CCNE1, LGALS8, ITGb3, ATP1B1, FLIP, KRT7 and KRT19) were validated by real-time quantitative PCR analysis and show differential expression between LMPs and TOVs. Immunohistochemistry analyses showed that the two tumor classes were distinguishable by their expression of CAS, TNFR1A, FLIP, CKS1 and CCNE1. These results define signature patterns for gene expression of LMPs and TOVs and identify gene candidates that warrant further study to deepen our understanding of the biology of EOC.
Introduction
In women, ovarian cancer is the fourth leading cause of deaths related to cancer and represents the most lethal gynecologic malignancy with a 5-year survival of 30-40% (Auersperg et al., 2001 ). Generally asymptomatic, over 70% of women are diagnosed with advanced disease. The most common pathology is epithelial ovarian cancer (EOC), which is classified by several criteria. Tumors are subdivided into three major classes: benign (BOV), low malignant potential or borderline (LMP) and invasive disease (TOV). Histologically, BOV tumors show no stratification and do not present atypical cells. LMPs show epithelial proliferation with stratification and cytologic atypia with no stromal invasion, although microinvasion can be observed (Tavassoli, 1988) . In contrast, TOVs exhibit a high mitotic index, cytologic atypia and stromal invasion (Burger et al., 2000; Dietel and Hauptmann, 2000) . Several histopathological subtypes are recognized including: serous, mucinous, endometrioid, clear cell and Brenner, as well as mixed and undifferentiated histopathologies. Grade defines the differentiation of tumors and varies from B, for LMPs tumors, and increases from grades 1 to 3 as TOVs appear less well differentiated. Tumors of stage I are confined to the ovaries while stage IV disease presents with distant metastasis (de Souza and Friedlander, 1992) .
LMPs represent 20% of malignant epithelial tumors and 60% of the tumors seen in young women (o40 years) (Trope and Kaern, 1998) . The major histopathological subtype of LMPs is serous and these tumors are generally much less aggressive than TOVs. In serous borderline disease, the 5-year survival is 90-95% for early stage disease and 55-70% in stage III disease (reviewed in Seidman and Kurman, 2000) . However, from 7 to 15% of LMPs can recur, generally as borderline disease, but upon recurrence the prognosis is similar to that of invasive carcinoma (reviewed in Seidman and Kurman, 2002) . Recurrent borderline disease may be associated with aneuploidy, high mitotic activity, microinvasion and/or a micropapillary serous carcinoma subtype (Link et al., 1996a; Dietel and Hauptmann, 2000; Seidman and Kurman, 2002) . The LMP disease is not well characterized at the molecular level and this probably underlies several issues related to these tumors. While there remains a debate as to whether LMPs represent an early precursor of invasive disease, more recent evidence supports a dualistic model that separates LMPs and TOVs along separate oncogenenic pathways. The notion of a separate LMP disease is supported by the observation that specific LMP loss of heterozygosity at chromosome Xq is not observed in low-grade tumors (Cheng et al., 1996) . In addition, the clonality of LMPs has been called into question by the observation that random X inactivation occurs within LMPs (Gu et al., 2001) . Additional molecular evidence also supports the notion that LMP disease does not progress to TOV but represents a separate disease entity (Link et al., 1996b; Ortiz et al., 2001; Singer et al., 2002 Singer et al., , 2003a .
The diagnosis of LMP has to be precise since conservative surgery is usually sufficient to control the disease without the need for chemotherapy (Gotlieb et al., 1998; Trope and Kaern, 1998) . However, the histological criteria allowing the distinction of LMPs from BOVs and TOVs are not always sharply defined. A misclassification may result in a suboptimal or sometimes overly aggressive therapeutic approach for the patient. In addition, defining the molecular relationship between ovarian LMPs and TOVs is an important strategy to understand the biology of the disease, and in particular may provide insights into the molecular pathways that impact negatively on prognosis as well as providing molecular markers to better define these EOCs.
While several groups have conducted expression profiling studies in invasive ovarian cancer (reviewed in Le Page et al., 2004) , little attention has focused on gene profiling of LMPs by DNA microarray (Lee et al., 2004) , partly due to the relative scarcity of these samples which only represent 20% of all EOCs. In this study, we used a DNA microarray approach to define molecular differences based on gene expression between LMPs and TOVs of the serous histopathological subtype. Two model systems were used for this analysis: tumor tissues and primary cultures derived from fresh tumor tissues. For each model system, we selected candidates by applying class prediction methods using three different statistical analyses. Each statistical method selected candidate genes allowing the distinction between the LMPs and TOVs and the proper reclassification of individual samples. Furthermore, real-time quantitative PCR (Q-PCR) analysis were performed on a subset of these candidates to validate the microarray data. Finally, we extended the analysis to address the protein expression of a limited number of candidates identified in our analysis using an immunohistochemical assay on clinical specimens representing both the borderline and invasive disease.
Results

Distinction between LMPs and TOVs tumor tissues using gene expression
We used the Affymetrix GeneCHIP HuGeneFL microarray to establish gene expression pattern of LMPs and TOVs. Samples were from chemotherapy naı¨ve patients and were further selected according to their malignancy (grade B for LMPs or grade 3 for TOVs) and serous histopathologic subtype (Table 1) . We used a total of six LMPs and 12 TOVs as the training set to identify differences between the two tumor classes using a preprocessed dataset comprised of 4447 probe sets. To identify the differential expression patterns between LMPs and TOVs, we performed three statistical tests that have been used independently in the analysis of expression microarrays: a signal-to-noise metric, a modified T-test (SAM) and the Mann-Whitney U test (Golub et al., 1999; Tusher et al., 2001; Troyanskaya et al., 2002) (Figure 1 ). Over 200 candidate genes were identified by the signal-to-noise ratio ( Figure 1a ) and LMP206  -B  IIIC  HuFL, IHC  TOV513G  -3  IIIC  HuFL, IHC  TOV540  8  3  IIIC  HuFL, IHC  LMP720G  14  B  IIIA  HuFL, IHC  TOV730EP  4  3  IIIC  HuFL  LMP793D  -B  IIIC  HuFL  TOV800 EP  -3  IIIC  HuFL  LMP845  -B  IIIC  HuFL, IHC  LMP849G  -B  IIIC  IHC  TOV881  3  3  IIIC  HuFL, IHC  TOV884D  3  3  IIIC  IHC  TOV892  5  3  IIIC  HuFL  TOV908D  5  3  IIIC  HuFL, IHC  LMP916  3  B  IIIA  HuFL, IHC  LMP920D  6  B  IIIA  HuFL, IHC  TOV952G  -3  IIIC  IHC  TOV959G  5  3  IIIC  HuFL, IHC  TOV960EP  5  3  IIIC  HuFL  TOV974G  -2  IIIC  IHC  LMP984  5  B  IB  HuFL, IHC  TOV986EP  -2  IIIC  HuFL, IHC  LMP991G  5  B  IB  HuFL, IHC  TOV993EP  -3  IIIC  HuFL, IHC  LMP1010D  4  B  IB  HuFL, IHC  LMP1010G  -B  IB  HuFL  TOV1054D  -3  IB  HuFL, IHC  TOV1054 G  -3  IB  HuFL, IHC  LMP1064D  -B  IA  IHC  LMP1068D  -B  IIIC  IHC  TOV1095 D  -3  IIIC  IHC  TOV1095G  -3  IIIC  IHC  TOV1108D  -3  IIIC  IHC  TOV1118D  -3  IIIC  IHC  TOV1142D  -3  IIIC  IHC  TOV1150D  -3  IIC  IHC  TOV1150G  -3  IIC  IHC  TOV1217EP  -3  IIIC  IHC LMP ¼ tumor of low malignancy potential; TOV ¼ primary invasive epithelial ovarian tumors; -¼ not applicable Figure 1d , expression values of the 137 genes common to all three statistical analyses are represented. These common genes were regrouped according to their biological functions using the NIH-DAVID GoCHART tool (Figure 1e ).
Complete gene lists for all statistical analyses are provided in Supplementary Figure 1 (a-e). The majority of the candidate genes are required in processes like nucleic acid or protein metabolism, transport, cell proliferation, signal transduction, biogenesis and catabolism.
Distinction between LMPs and TOVs primary cultures using gene expression
We performed similar analyses using a training set of primary cultures derived from six LMPs and eight TOVs independent samples. In comparison to tumor tissues, this model system has been demonstrated to be enriched in tumor cells (Lounis et al., 1994; Tonin et al., 2001) . After the preprocessing of the data, 3865 genes served in the subsequent analysis. Figure 2a , provides the expression results for the 194 genes (B5%) selected by the signal-to-noise analysis while Figure 2b presents the profile for the 174 genes selected using the MannWhitney U test (P ¼ 0.02). Among these candidates, 147 were common to both analyses. Figure 2c , represents profiles for the 146 genes selected with SAM including the 133 genes common with the signal-to-noise analysis ( Figure 2a ) and the 121 common with the MannWhitney U test (Figure 2b ). Figure 2d represents the expression of the 116 genes common between the three statistical analyses. Complete gene lists for all statistical analyses are provided in Supplementary Figure 2 (a-e). Genes that were regrouped based on major biological processes are presented in Figure 2e and included protein and nucleic acid metabolisms as well as cell proliferation, signal transduction and organogenesis. The majority of these cellular processes were also observed in tumor tissues analysis (Figure 1e ) supporting their role in carcinogenesis.
Model system comparison
Comparison between the restricted set of common genes (B100 for each model) selected in the primary culture or tumor tissue model systems (Figures 1d and 2d ) identified only seven genes common to both lists: cellular apoptosis susceptibility (CAS), cyclin E1 (CCNE1), chromobox homolog 1 (CBX1), CDC28 protein kinase 2 (CKS2), apical protein (APXL), capping protein (CAPG) and heterogeneous nuclear ribonucleoprotein M (HNRPM). To further compare the two model systems, we extracted gene expression data from tissue culture samples for the common candidates identified in the tumor model and vice versa (Figure 3a and b) . This allowed us to determine that the differential expression of common candidates selected in one model continued to discriminate LMPs from TOVs in the alternate model.
Use of the candidate genes for class prediction
The selection of candidate genes that allow distinction between the LMPs and the TOVs could be used to either reclassify samples, using the weighted voting score, from the original training set or to classify new samples. In Figure 4 , we present the prediction strength calculated upon reclassification of the training sets for tumor tissues ( Figure 4a ) and primary cultures (Figure 4b) . A positive value represents assignment to the LMP class and a negative value corresponds to assignment to the TOV class. The candidate genes selected by each statistical test (signal-to-noise, SAM and U) allowed the correct classification (over 0.3 for LMPs and below À0.3 for TOVs) of all samples either in tumor tissues or primary cultures. In general, we observed that the common genes (137 for tumor tissues or 116 for primary cultures) appeared to classify samples with a higher prediction strength than each of the three statistical methods independently. We also determined whether candidates identified in one model system could successfully be used to classify samples in the alternate model system. Interestingly, tumor tissue candidates were unable to distinguish the LMPs in primary cultures as all samples were classified as TOVs. In contrast, primary culture candidates retained the ability to classify tissue samples with 13 correctly assigned, one sample incorrectly assigned (an LMP sample), and four samples were not classifiable (both LMPs and TOVs samples).
To further test the strength of the selected candidates, we used the common tissue-specific candidates to classify ovarian tumor samples from publicly available datasets where profiling was accomplished using ovarian tumor tissue arrayed on the Affymetrix HuGeneFL (Schwartz et al., 2002) . Of these 113 tumor tissues where public datasets were available, 100% were correctly classified, irrespective of the different histopathologicial subtypes (55 serous, 10 mucinous, 33 endometrioid, eight clear cell and nine mixed cell), differences in tumor grades (grades 1-4) and disease presentation (Stages 1-IV) included in the analysis. The candidates derived from the analysis of primary cultures of LMP and TOV tumors correctly predicted 85 solid tumors, but failed to predict the classification of 25 samples and misclassified three samples. We also used the common candidates from primary culture to classify ovarian cultures arrayed on the Affymetrix U95 (Matei et al., 2002) . Despite the fact that only a portion of the candidates (95/116) are appropriately represented on the U95 array, all 21 primary cultures derived from TOVs were appropriately classified with a high prediction strength.
Q-PCR validation of candidate genes
PCR was performed to validate the biological relevance of a subset of the common genes (Figures 1d and 2d ) that appeared to differentiate LMPs from TOVs by microarray analysis. The selection of candidate genes h), using ERK1 as an internal control. The Q-PCR was performed on a subset of the samples that served in the microarray analysis. The level of mRNA showed statistically significant differences (Po0.05) between LMPs and TOVs for CCNE1 (P ¼ 0.002), KRT19 (P ¼ 0.01), KRT7 (P ¼ 0.02), ATP1B1 (P ¼ 0.001) and FLIP (P ¼ 0.05), while near significance was reached with CAS (P ¼ 0.07), ITGB3 (P ¼ 0.08) and LGALS8 (P ¼ 0.09) ( Figure 5 ). These results confirmed those obtained by microarray analysis in either tumor tissues or primary cultures. However, we also performed Q-PCR analysis for CKS1, RHEB2 and GPI on tumor tissue samples and these genes failed to demonstrate a significant difference between LMPs and TOVs (data not shown). Similarly, TNFR1A, ELF2, CAS and CCNE, all differentially expressed by microarray in primary cultures, did not produce statistically significant differences by Q-PCR when comparing LMPs and TOVs (data not shown). Therefore, we were able to confirm the differential expression of a subset candidate genes identified by microarray, although the correlation was not supported by Q-PCR results for a number of candidates.
Immunohistochemistry
In order to define if the corresponding protein expression of the candidate genes could serve as a molecular marker to distinguish LMPs from TOVs, we performed immunohistochemistry (IHC) on the tumor tissues of 12 LMPs and 12 TOVs. Tissues were scored for both the extent and intensity of staining. Characteristic staining as well as numerical calculations of expression are presented in Figure 6 . Significant differences between LMPs and TOVs were observed for CCNE1 (P ¼ 0.08), CAS (P ¼ 0.005), CKS1 (P ¼ 0.0005), FLIP (Po0.0001), and TNFR1A (P ¼ 0.0003) protein expression. However, while these candidates exhibited significant differences in expression when entire groups were compared, within individual samples variations were observed and no marker alone could correctly predict the assignment of LMP and TOV samples. The levels of KRT19 and KRT7 proteins were also monitored, and although clear differences were seen by microarray and Q-PCR analyses, no significant differences were noted by IHC (P ¼ 0.62 and 0.20, respectively).
Discussion
Based on Affymetrix HuGeneFL microarray datasets, we selected candidate genes defining differential gene expression between LMPs and TOVs using different statistical approaches in both tumor tissue and primary culture model systems. In both model systems, our candidate genes allowed the proper classification of all samples used in this study. In addition, the selected candidates were able to classify tumors from published data, including other histopathology subtypes, reinforcing the usefulness and the validity of the selected candidates. While candidates selected in both model systems were largely different, seven genes were common to both tumor tissues and primary cultures. Interestingly, these seven genes allowed the proper classification of all samples used in this study and correctly classified 86% of the samples from an independent public dataset (Schwartz et al., 2002) . We also assessed the differential expression of a subset of genes by Q-PCR analysis, with over half of the candidates displaying statistically significant difference between LMPs and TOVs. The lack of significance for the remaining candidates tested may be due to probe set selection on the Affymetrix array, the low expression level of some genes or to the technical limitation imposed by the Q-PCR technique which does not allow the distinction of less than two-fold difference in gene expression. Attempts to reclassify LMP or TOV samples using the Q-PCR data provide limited success as only 64% of samples derived from primary cultures and 67% of samples derived from tumor tissues being correctly classified. These low reclassification scores were mainly due to unclassifiable samples while only a small number of samples were incorrectly assigned (14% for primary cultures and 0% in tumor tissues). This suggests that classification by Q-PCR is attainable although further refinements of candidates may permit a more robust reclassification of samples. We also identified protein expression patterns for a limited number of candidates using IHC. While overall differences between LMPs and TOVs were observed for some candidates, the use of one marker was not sufficient to clearly assign individual samples into either class, and probably the combination of several optimally chosen markers will ultimately be needed to allow the clear assignment of LMPs and TOVs. For both model systems, selected candidates could be grouped according to function, with high expression of genes involved nucleic acid and protein metabolism, cell proliferation and signal transduction in the TOVs. This is consistent with the fact that TOVs have higher proliferation rate than LMPs (Halperin et al., 2001; Kitakata et al., 2002) .
Common candidate genes identified in tumor tissues were cross-referenced to available literature on gene differentially expressed in EOC identified either by microarray analysis or by other techniques. Of a total of 137 genes, 43 have previously been described in EOC (Table 2) . Among these genes, 35 were identified by microarray analysis, 11 were identified by other RNAbased detection techniques and 20 were studied at the protein level. The expression level of 37 genes was concordant with previously reported results while the direction of expression was discrepant and noninformative for six and nine genes, respectively. Likewise, in the primary culture model, 26 genes have already been identified by other groups as differentially expressed in ovarian malignancy either by microarray analysis or by other techniques (summarized in Table 3 ). These candidates were identified by either microarray analysis (14 genes/ESTs), by other RNA monitoring techniques (six genes) or studied at the protein level (14 genes), and shown to be differentially expressed in EOC. The direction of differential expression matched published results for 15 genes identified while 10 were uninformative and six showed differential expression opposite to reported results (Table 3) .
In the present study, we compared both tumor tissues and primary cultures derived from a fresh tumor tissues. The first model is probably more representative of the disease but presents contamination of stromal cells and/ or infiltrating cells. In contrast, the primary culture model is enriched of tumor cells (Lounis et al., 1994) from which we can extract high-quality RNA, but the culture condition and loss of microenvironment interaction may influence the genetic expression. Cross comparison between the models suggest little overlap in the actual candidates, although the primary culture selected candidates in particular allow a better distinction between tissues derived from LMPs and TOVs. Within the candidates that were common to both model systems (seven genes), the trend of expression was similar except for APXL. Similarly, cross comparisons of candidates unique to one model system also showed similar trends of expression when assessed in the alternate model, with only a few genes displaying significant differences (including FLIP, SR-BP1, GSTP1 and DUSP4). While these results demonstrate the general concordance between the two model systems, they also highlight the fact that genes may be modulated by either the microenvironment or the presence of multiple cell types in the case of tumor tissues. Indeed, we noted twice as many candidate genes in tumor tissues versus primary cultures classified in biological processes that may reflect the influence of the microenvironment such as response to external stimulus, response to stress and immune responses. As an example, NMI, which is actively transcribed in response to IL2 and IFNg secreted by the immune system cells including activated T-and B cells, is more highly expressed in tumor tissues than in primary cultures. Our results also support the notion that primary cultures help define differences in expression present in tumor tissues that may be masked by strong candidates derived from cell types other than the tumor cells themselves and this would also explain why tumor tissue candidates classify primary cultures poorly. Nonetheless, even if a subset of tumor tissue candidates are derived from either epigenetic events associated with stroma, or alterations of cell populations associated with tumor tissues, they remain indirect Figure 5 Validation of the candidate genes by Q-PCR. The analysis was done using the Pfaffl analysis method using ERK1 as the internal control gene and statistical analysis was performed using the Mann-Whitney U test. The candidates tested were: (a) CCNE1 indicators of fundamental differences in the biology associated with LMPs and TOVs. A number of the candidate genes identified in this report have already been identified in ovarian cancer and the observed expression profile is consistent with previously reported results. Among those candidates, we count CAS, CCNE1, GPI, PRSS8 and CK2B in the tumor tissue model system and CAS, CCNE1, HOXB7, LDHB and LAMb1 in the primary culture model, which have been studied both at the RNA and protein levels, often in several studies (see Tables 2 and 3 LMP720G  LMP845D  LMP849G  LMP920D  LMP984D  LMP991G  LMP1010D  LMP1036D  LMP1064D  LMP1068D  TOV513G  TOV540G  TOV881EP  TOV884D  TOV908D  TOV952D  TOV959D  TOV974G  TOV986EP  TOV993EP  TOV1054D  TOV1054G   Intensity   0   20   40   60   80   100   LMP206  LMP720G  LMP845D  LMP849G  LMP916D  LMP920D  LMP984D  LMP991G  LMP1010D  LMP1036D  LMP1064D  LMP1068D  TOV513G  TOV540G  TOV881EP  TOV884D  TOV908D  TOV952D  TOV959D  TOV974G  TOV986EP  TOV993EP  TOV1054D  TOV1054G   Intensity   0   20   40   60   80   100   LMP206  LMP720G  LMP845D  LMP849G  LMP916D  LMP920D  LMP984D  LMP991G  LMP1010D  LMP1036D  LMP1064D  LMP1068D  TOV513G  TOV540G  TOV881EP  TOV884D  TOV908D  TOV952D  TOV959D  TOV974G  TOV986EP  TOV993EP  TOV1054D  TOV1054G   Intensity   0   20   40   60   80   100   LMP206  LMP720G  LMP845D  LMP849G  LMP916D  LMP920D  LMP984D  LMP991G  LMP1010D  LMP1036D  LMP1064D  LMP1068D  TOV513G  TOV540G  TOV881EP  TOV884D  TOV908D  TOV952D  TOV959D  TOV974G  TOV986EP  TOV993EP  TOV1054D  TOV1054G   Intensity   0   20   40   60   80   100   LMP206  LMP720G  LMP845D  LMP849G  LMP916D  LMP920D  LMP984D  LMP991G  LMP1010D  LMP1036D  LMP1064D  LMP1068D  TOV513G  TOV540G  TOV881EP  TOV884D  TOV908D  TOV952D  TOV959D  TOV974G  TOV986EP  TOV993EP  TOV1054D number of candidates reinforce the implication of these genes in ovarian carcinogenesis as well as supporting the potential role of the additional candidates we identified in EOC. While concordance with published results was high, notable exceptions were observed. In studies focusing on microarray data, some of these discrepancies could be attributed to differences to the reference group used for comparison with TOVs that often consisted of normal ovarian tissue or normal ovarian cell cultures (either primary cultures or viral oncogene immortalized cell lines) or that only protein levels were assessed, and thus not directly comparable to microarray results. A number of specific candidates have been prominently featured in previous reports in EOC and other cancers. These include ITGb3 and LGALS8, both of which appear to be underexpressed in TOVs, by both microarray and Q-PCR analyses. This is in agreement with a previous report describing the underexpression of the b3 subunit in high-grade tumors of the EOC compared to low-grade and borderline tumors (Carreiras et al., 1996) . In addition, it has been shown that LGALS8 protein expression is significantly decreased in tumors of the pancreas, colon, liver and larynx (Danguy et al., 2002) . A larger number of genes thought to be associated with tumorigenesis have been shown to be overexpressed in TOVs in our microarray analysis. These include GPI whose expression correlates with increased motility and metastatic activity of tumor cells (Yanagawa et al., 2004) and whose overexpression in ovarian tumors has previously been reported (Lee et al., 2004) .
Of the candidates identified in our study, several cell cycle regulators appear to be of particular interest. These include CCNE1 (otherwise known as cyclin E), which binds CDK2 and is required for the G1 -S phase progression. In agreement with our study of both primary cultures and tumor tissues, CCNE1 has been shown to be overexpressed in many types of cancer. In particular, CCNE1 was shown amplified by FISH analysis in different tumor types including EOCs (Schraml et al., 2003) . The overexpression of CCNE1 was observed at the mRNA (30%) and protein (43%) level in ovarian tumors compared to normal ovaries (Sawasaki et al., 2001) and was also associated with a poor prognosis (Rosenberg et al., 2001; Sui et al., 2001a; Farley et al., 2003; Milde-Langosch et al., 2003; Schraml et al., 2003) . Moreover, a gradation in CCNE1 expression from benign to LMPs (50%) and to TOVs (70%) has also been reported (Sui et al., 2001a) . Our results support previous results and contribute to the expectation that CCNE1 plays a role in EOC. A second cell cycle regulator of particular interest is CKS1 which favors anaphase through its modulation of the transcription of CDC20 (Patra et al., 1999; Morris et al., 2003) . CDC20 is required to bind and activate the ubiquitin activity of the anaphase-promoting complex (APC) which targets cyclin B to the proteasome, in turn promoting the end of mitosis. CKS1 has also been reported to target p27kip, an inhibitor of G1 cyclins, to the ubiquitin-mediated proteolysis allowing progression through the cell cycle (Harper, 2001) . CKS1À/À knockout mice are unusually small and the cells derived from these mice proliferate slowly in association with the accumulation of p27Kip (Spruck et al., 2001) . We observed overexpression of CKS1 in TOVs in tumor tissues, which correlates with the reported overexpression in colorectal (Shapira et al., 2004) , gastric (Masuda et al., 2003) , lung (Inui et al., 2003) and fibrosarcomas (Gascoyne et al., 2003) . Together, results with CKS1 and CCNE1 suggest that the cell cycle can be targeted at different levels in EOC.
Another potential candidate that can contribute to the deregulation of the cell cycle is CAS (for Cellular Apoptosis Susceptibility), whose overexpression was observed in TOVs by microarray analysis (in both model systems), Q-PCR and IHC. CAS has a role in both proliferation and apoptosis. CAS is required for the recycling of the nuclear transporter importin-a assisted by RANGTP, RANBP and RANGAP (Kutay et al., 1997) . RANBP1 as well as RAN were also found to be overexpressed in TOVs compared to LMPs in the tumor tissue model system further supporting a role for this pathway in TOVs. Proteins whose nuclear localization is influenced by importin a include cell cycle and apoptosis proteins such as CDK, Cyclin/CDK complexes, as well as p53, Rb and NF-kB (Brinkmann, 1998) . CAS has already been shown to be amplified in leukemia, colon and breast cancer by in situ hybridization and Southern blot analysis (Brinkmann, 1998) . Recently, it was shown by IHC that CAS is overexpressed in EOC TOVs compared to LMPs (Brustmann, 2004) . CAS overexpression has also been observed to be associated with high stage and grade EOC tumors as well as with residual disease (Peiro et al., 2002) . By FISH, CAS was found to be amplified in tumors of the serous and endometrioid histopathology subtypes as compared to mucinous and clear cell tumors (Peiro et al., 2002) . Together, these observations support the importance of CAS deregulation in EOCs and once again point to the usefulness of the microarray approach.
In conclusion, in the present study we demonstrate the validity of using signature expression patterns to distinguish between LMP and invasive EOCs. The candidates identified are not only useful in defining these two entities, but also provide support for the notion that LMPs are a clearly identifiable entity separate from TOVs. In addition, although LMPs and TOVs share several pathways that are similarly modulated in these cancers with very different prognosis, the differences that define LMPs and TOVs point to key regulators that may influence invasiveness and prognosis and as such provides new insight for the identification for more appropriate therapeutic targets in aggressive EOCs. From a clinical point, a further goal of the molecular characterization of the LMPs will be the identification of molecular markers defining the subset of LMPs which progress to an aggressive disease, and this study provides a starting point to begin to address whether poor prognosis LMPs share more common characteristics and would be characterized as LMPs (1998) or TOVs using the candidate genes identified in this study.
Materials and methods
Cell culture and clinical material
Primary cell cultures from EOC samples were established as described (Kruk et al., 1990; Lounis et al., 1994) . Cells were maintained in OSE media consisting of 50 : 50 medium 199 : 105 (Sigma) supplemented with 10% fetal bovine serum (FBS), 2.5 mg/ml amphotericin B and 50 mg/ml gentamicin (Kruk et al., 1990) . Following appropriate consent, tumor samples were collected following surgeries performed at the Centre Hospitalier de l'Universite´de Montre´al (Hoˆpital Notre-Dame). Histopathology, grade and stage of tumors were assigned according to the International Federation of Gynecology and Obstetrics (FIGO) criteria. All samples selected in the study received an additional pathology review by a certified gynecologic pathologist. Only tumors of serous histopathology subtype and from chemotherapy naı¨ve patients were used. Tumor tissues from six LMPs and 12 TOVs as well as primary culture from six LMPs and eight TOVs model system were used in the microarray analysis training set while tissues of 12 LMPs and 12 TOVs were used in the immunohistochemistry study. Profiles associated with samples are presented in Table 1 . For the LMP disease, only one patient (991) is known to have recurred with ovarian disease of the same grade and histopathology.
RNA extraction
Total RNA was extracted with TRIzolt reagent (Gibco/BRL, Life Technologies Inc., Grand Island, NY, USA). RNA was either extracted directly from the homogenized tumor tissue or from the tumor cells grown to 80% confluency in 100 mm Petri dishes. The quality of the RNA was assessed using a 2100 Bioanalyzer with the RNA 6000 Nano LabChip kit (Agilent Technologies, Mississauga, ON, Canada) according to the manufacturer's protocol.
Microarray analysis
The hybridization assays and data collection of expression values were performed at the McGill University and Genome Quebec Innovation Centre (Montreal, Canada). Briefly, 20 mg of total RNA from each sample was reverse transcribed using oligo-dT primer containing a T7 RNA polymerase-binding site. An in vitro transcription was performed on this cDNA and the resulting cRNA was biotinylated via incorporation of biotinylated dUTP and dCTP. DNA from samples was fragmented in 40 mM Tris acetate, 100 mM potassium acetate, and 30 mM MgCl 2 (pH 8.1) at 951C in order to reduce secondary structure. A measure of 15 mg of cRNA was hybridized to an Affymetrix HuGeneFL microarray, washed, stained and scanned with a Hewlett Packard Gene Array scanner. Raw values were assigned by Affymetrix GeneChip software (Mas 4) for each probe set from the scanned image with an accompanying reliability score of Present (P), Marginal (M) or Ambiguous (A).
Preprocessing of data
To allow interarray comparisons, raw data were normalized for each array by dividing the value obtained for each probe set by the average of the expression values of the whole set and then multiplying the resulting value by 100 as previously described . After normalization, we considered all values below 20 as technical noise and increased to 20 all expression values below this threshold. All probe sets having an expression value of 20 across all samples in addition to probe sets where an A call was present in all samples were discarded. The log 10 of all remaining values were then calculated and used in all subsequent analyses. Both the raw and normalized datasets are available at http://www.genomequebec.mcgill.ca/ovarian/.
Statistical analysis
Candidate genes that allow the distinction between the two a priori defined classes of samples under study, that is, class 1 (LMP) and class 2 (TOV), were selected according to three different statistical tests: a signal-to-noise metric, a modified Ttest using SAM and a nonparametric test. The signal-to-noise ratio S2N ¼ (m 1 Àm 2 )/(s 1 þ s 2 ) has been described and tested where m represents the mean and s the standard deviation of either class 1 or 2 (Golub et al., 1999; Ramaswamy et al., 2001) . The top 5% were considered for further analysis. The modified T-test was computed with the Significance Analysis of Microarray (SAM) as described (http://www-stat-class.-standford.edu/SAM/SAMServlet) (Tusher et al., 2001) . We performed 1000 permutations in an unpaired data set for each comparison. In order to limit the false discovery rate (FDR) and thus number of false-positive genes, and to preserve the sensitivity of the test, a threshold D was chosen. The nonparametric test of Mann-Whitney (U) using GeneSpringt software (Silicon Genetics, Redwood City, CA, USA) was also performed (Troyanskaya et al., 2002) . Candidate genes were first selected to give a difference of expression with a significance of at least 0.05 thus providing a number of candidates roughly equal to the previous two analyses. DAVID tools GoChart (http://apps1.niaid.nih.gov/david/) was used to annotate and classify candidate genes selected by the various algorithms according to major biological processes.
To confirm the predictive value of our set of candidate genes a weighted voting score was used to reclassify samples from our training set as LMPs or TOVs (Golub et al., 1999; Ramaswamy et al., 2001) . To predict the class of samples derived from public datasets with our set of candidates (Matei et al., 2002; Schwartz et al., 2002) , a K-nearest neighborhood analysis was computed with GeneSpringt software (Silicon Genetics, Redwood City, CA, USA).
RNA amplification procedure (RAMP)
For linear amplification by RAMP (Alethia Biotherapeutics, Montreal, QC, Canada), first-strand cDNA was synthesized from 100 ng of total RNA using Thermoscript reverse transcriptase (Invitrogen Life Technologies, Carlsbad, CA, USA) followed by RNA hydrolysis with RNase A and RNase H. A specialized oligonucleotide mixture comprising a 5 0 -sequence tag and a randomized 3 0 -sequence was hybridized to the cDNA molecules, and the cDNA was extended using a DNA polymerase enzyme and the oligonucleotide as template. Subsequently, the complement to the oligonucleotide sequence tag was added to the 3 0 -ends of cDNA molecules. Thereafter, an oligonucleotide primer containing the T7 RNA polymerase promoter sequence was added to the cDNAs via the sequence tag and in vitro transcription was performed using MegaScript Kit (Ambion Inc., Austin, TX, USA). To further increase the amplification yield, the transcribed RNA was converted to first-strand cDNA (Invitrogen Life Technologies, Carlsbad, CA, USA) followed by second-strand DNA synthesis using the T7 RNA polymerase promoter primer. In vitro transcription (Ambion Inc., Austin, TX, USA) was again performed and the amplified RNA purified using RNeasy columns (QIAGEN Inc., Mississauga, ON, Canada). The RAMP RNA produced is ( þ ) sense.
Q-PCR
cDNA synthesis was done according to protocols provided with the SuperScriptt First-Strand Synthesis System for RT-PCR (Invitrogen Life Technologies, Carlsbad, CA, USA). RT-PCR was performed on 2 mg of total RNA using 2.5 ml of the random hexamer solution. Samples were diluted 1/50 in water prior to Q-PCR. Appropriate PCR conditions (temperature, specificity) were determined using conventional PCR. Positive and negative controls were introduced in all experiments. Amplicons were digested with appropriate restriction enzymes to confirm the specificity of the amplification.
Q-PCR was performed using the Rotor-gene 3000 RealTime Centrifugal DNA Amplification System (Corbett Research, Montreal Biotech Inc., Montreal, QC, Canada). Quantitectt SYBR Green PCR (QIAGEN Inc., Mississauga, ON, Canada) was used for labeling in a final volume of 25 ml containing 5 ml of sample cDNA and 10 pg of the different primers and reactions performed as described by the manufacturer. Experiments were repeated at least twice. Serial dilutions (1 : 5) were performed to generate a standard curve for each gene tested in order to define the efficiency of the Q-PCR reaction and a melt curve was done to confirm the specificity of the reaction. The primers are listed in Supplementary Table 1 . We used the Pfaffl analysis method to measure the relative quantity of gene expression (Pfaffl, 2001 ). The algorithm is defined by R ¼ ðE target Þ DCptargetðcontrolÀsampleÞ =ðE ref Þ
DCprefðcontrolÀsampleÞ
where R is the relative expression ratio, E the efficiency of the PCR reaction, and DCp the difference of the Ct (crossing point of the sample at a giving threshold). The reference gene, ERK1, was selected based on its stable expression in all samples in both model systems in microarray analysis and further Q-PCR confirmed its appropriateness since no significant statistical difference was noted in either tumor tissue (P ¼ 0.93) or primary culture (P ¼ 0.30). Our first sample served as the reference sample in each experiment. The mean value of the Ct from replicates were taken to calculate the R. A MannWhitney nonparametric test was further computed for each experiment by using the Statviewt software (SAS, San Francisco, CA, USA) in order to verify that the difference of expression between the two classes of samples was statistically significant.
Immunohistochemistry
The following antibodies were used in immunohistochemistry: anti-CAS goat polyclonal antibody sc-1709 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-CCNE1 rabbit polyclonal antibody sc-198 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-CKS1 goat polyclonal antibody sc-12986 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-TNFR1 rabbit polyclonal antibody sc-7895 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-FLIPS/L rabbit polyclonal sc-8347 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-KRT7 mouse monoclonal antibody Ab-2 (clone OV-TL 12/30) Neomarkers (Medicorp, Montreal, QC, Canada) and anti-KRT19 mouse monoclonal antibody Ab-3 (Medicorp, Montreal, QC, Canada). Formalin-fixed, paraffin-embedded tumor specimens were sectioned and stained by an immunoperoxidase method. Briefly, tissue sections were heated at 601C during 30 min, deparaffinized in toluene and rehydrated in a gradient of ethanol. Following a treatment with 3% H 2 O 2 to eliminate endogenous peroxidase activity, slides were submerged in boiling citrate buffer (0.01 M citric acid adjusted to pH 6.0) (JT Baker Philipsburg, NJ, USA) for 15 min unmask antigen. The sections were blocked with a protein blocking serum-free reagent (DakoCytomation Inc., Mississauga, ON, Canada) and incubated with the different antibodies for 60 min at room temperature. The optimal concentration for each primary antibody was determined by serial dilutions. Tissues were incubated with the secondary biotinylated antibody (DakoCytomation Inc., Mississauga, ON, Canada) or with the rabbit anti-goat biotin-conjugated antibody (1 : 300) (sc-2774, Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 20 min followed by incubation with streptavidin-peroxidase complex (Dako Diagnostics Canada Inc.) for 20 min at room temperature. Reaction products were developed using diaminobenzidine containing 0.3% H 2 O 2 as a substrate for peroxidase, nuclei were counterstained with hematoxylin and all staining was observed by light microscopy at Â 20 magnification. Substitution of the primary antibody with phosphate-buffered saline served as a negative control. Representative malignant zones (minimum of three) were scored according to the extent (as a % of total malignant cells) and intensity (value of 0 for absence, 1 for low, 2 for moderate and 3 for high intensity) of staining. All slides were independently analysed in a blind study by two independent observers. Statistical analyses were performed using the Mann-Whitney U test. for immunohistochemistry, and Mario Filion for linear amplifications of RNA. We thank Dr A Alobaid for thoughtful comments. This work was supported by a grant from the Canadian Institutes of Health Research (CIHR) to A-MM-M, PNT, DMP and TJH. We recognize also the Fondation Jocelyn Gauvin for initial assistance in this research. 
